Uptravi Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Selexipag

Indications/Uses

Pulmonary arterial HTN.

Dosage/Direction for Use

Individualised dosage. Initially 200 mcg bd, approx 12 hr apart. Dose is increased in 200 mcg bd, usually at wkly intervals or until max dose of 1,600 mcg bd is reached.

Administration

May be taken with or without food: Take consistently w/ or w/o food. May be taken w/ meals to improve tolerability. Swallow whole, do not chew/crush/split.

Contraindications

Hypersensitivity. Severe coronary heart disease or unstable angina. MI w/in the last 6 mth. Decompensated cardiac failure if not under close medical supervision. Severe arrhythmias. Cerebrovascular events (eg, transient ischaemic attack, stroke) w/in the last 3 mth. Congenital or acquired valvular defects w/ clinically relevant myocardial function disorders not related to pulmonary HTN. Concomitant use of strong CYP2C8 inhibitors (eg, gemfibrozil). Severe hepatic impairment (Child-Pugh class C).

MIMS Class

Other Cardiovascular Drugs

ATC Classification

B01AC27 - selexipag ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.

Regulatory Classification

POM

Presentation/Packing

Form

Uptravi FC tab 1,000 mcg

Packing/Price

1's

Form

Uptravi FC tab 1,200 mcg

Packing/Price

1's

Form

Uptravi FC tab 1,400 mcg

Packing/Price

1's

Form

Uptravi FC tab 1,600 mcg

Packing/Price

1's

Form

Uptravi FC tab 200 mcg

Packing/Price

1's

Form

Uptravi FC tab 400 mcg

Packing/Price

1's

Form

Uptravi FC tab 600 mcg

Packing/Price

1's

Form

Uptravi FC tab 800 mcg

Packing/Price

1's

Uptravi

selexipag

Manufacturer:

Excella